2024
Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial
San Tham L, Heerspink H, Wang X, Verdino P, Saifan C, Benson E, Goldsmith P, Wang Z, Testani J, Haupt A, Sam F, Cherney D. Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial. Nephrology Dialysis Transplantation 2024, gfae112. PMID: 38782726, DOI: 10.1093/ndt/gfae112.Peer-Reviewed Original ResearchMeasured glomerular filtration rateEffective renal plasma flowRenal plasma flowKidney perfusionIncreased renal plasma flowPlacebo-adjusted changeMultiple-ascending dosePhase 1 trialGlomerular filtration rateChronic heart failureChronic kidney diseaseDiastolic blood pressureRenal arteriolar resistanceExtended half-lifeCardiorenal functionDouble-blindPlacebo SCRelaxin proteinSC doseAdverse eventsMeasured GFRArteriolar resistanceClinical developmentHeart failureOrthostatic hypotension
2021
Renal Hemodynamics and Renin-Angiotensin-Aldosterone System Profiles in Patients With Heart Failure
Lytvyn Y, Burns KD, Testani JM, Lytvyn A, Ambinathan JPN, Osuntokun O, Godoy LC, Cherney DZI, Parker JD. Renal Hemodynamics and Renin-Angiotensin-Aldosterone System Profiles in Patients With Heart Failure. Journal Of Cardiac Failure 2021, 28: 385-393. PMID: 34487814, DOI: 10.1016/j.cardfail.2021.08.015.Peer-Reviewed Original ResearchConceptsPlasma renin activityRenal blood flowAngiotensin converting enzymeHeart failureArteriolar resistanceGreater renal vascular resistanceEffective renal plasma flowRenal hemodynamic functionRenal vascular resistanceGlomerular filtration rateRenal plasma flowCardiorenal pathophysiologyGomez's equationsLower ERPFAldosterone systemIntravenous dobutamineNeurohormonal activationRenal hemodynamicsRenin activityVascular resistanceRenal profileRenin-AngiotensinHemodynamic functionLower GFRRenal vein